Takeda to sell select non-core assets to Cheplapharm for $562m
Takeda Pharmaceutical has agreed to sell a portfolio of certain non-core prescription pharma products sold mainly in Europe and Canada to German pharma company Cheplapharm for about $562 million. The portfolio to be offloaded to Cheplapharm is made up of non-core prescription pharma products in a range of therapeutic segments. This includes cardiovascular/metabolic and anti-inflammatory […]